Insider Transactions in Q3 2025 at Amylyx Pharmaceuticals, Inc. (AMLX)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2025
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,039
-6.19%
|
$168,546
$14.58 P/Share
|
|
Sep 30
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
29,933
-0.45%
|
$419,062
$14.67 P/Share
|
|
Sep 30
2025
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,558
-3.63%
|
$147,812
$14.65 P/Share
|
|
Sep 30
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,828
-5.62%
|
$123,592
$14.58 P/Share
|
|
Sep 30
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
29,975
-0.45%
|
$419,650
$14.69 P/Share
|
|
Aug 13
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,000
-8.72%
|
$120,000
$8.34 P/Share
|
|
Aug 12
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,000
-8.02%
|
$120,000
$8.07 P/Share
|